Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan to Prevent Renal Dysfunction in ADHF
NCT01663662Phase 4Withdrawn
- Sponsor
- University of Michigan
- Start
- Aug 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure (HF) comparing Tolvaptan Arm with Placebo Arm (2 arms). Primary endpoint: Renal dysfunction at 96 hours. Planned start Aug 2012; status: withdrawn.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01663662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663662.